AMT-110

N/A

Report date: 2024/11/27 20:00:40

Base Information

Drug NameAMT-110
Drug Alias NameAMT110rAAV2/5-hNAGLU
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2/5 vector
Mechanisms of ActionAlpha-N-acetylglucosaminidase replacementsAlpha-N-acetylglucosaminidase gene transference
TargetsAlpha-N-acetylglucosaminidaseHeparan sulfate
Therapy Area/IndicationsMucopolysaccharidosis III
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInstitute of Immunology and Infection, Chinese Academy of Sciences ShanghaiUniqure
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniqure Biopharma Bv
Active IndicationsN/A
Inactive IndicationsMucopolysaccharidosis III

Other Information

ATC CodeN/A
Related LinksN/A